Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
From radiolabeling and biodistribution to dosimetry and efficacy in diverse animal models, Perceptive Discovery delivers integrated, translatable data to accelerate your radiopharmaceutical pipeline from concept to clinic.
Perceptive Discovery offers comprehensive preclinical RLT services to support the discovery and development of radiopharmaceutical therapies. We work with biotech and pharmaceutical teams to design and execute custom studies that generate the translational data needed for IND submission and clinical advancement.
Our team of radiochemists, pharmacologists, cancer biologists, and imaging scientists bring deep expertise across a broad spectrum of isotopes, modalities, and therapeutic platforms. Whether developing a novel targeted radiotherapeutic or a companion diagnostic, we streamline radiolabeling, dosimetry, efficacy, and image analysis—all under one roof.
With over 900+ preclinical RLT studies supported, and 50+ IND-enabling dosimetry studies, we are a proven partner in bringing first-in-class radiopharmaceuticals to the clinic.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
Let’s design a translational imaging strategy to de-risk development and accelerate your radioligand therapy program.
Highly established clinical and imaging centers supporting first-in-human and multicenter studies.
Proven expertise in delivering high-quality clinical trial imaging data at a global scale.
